A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE) - Trial NCT06340490
Access comprehensive clinical trial information for NCT06340490 through Pure Global AI's free database. This Phase 1 trial is sponsored by Guangdong Ruishun Biotech Co., Ltd and is currently Not yet recruiting. The study focuses on Systemic Lupus Erythematosus. Target enrollment is 24 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Guangdong Ruishun Biotech Co., Ltd
Timeline & Enrollment
Phase 1
May 15, 2024
Dec 31, 2027
Primary Outcome
Dose-Limiting Toxicity (DLT),Maximum Tolerated Dose (MTD),Incidence of abnormalities
Summary
This study is an open-label, single-arm, dose escalation and dose expansion study to evaluate
 the safety, maximum tolerated dose, pharmacokinetic characteristics of allogeneic
 CD19-CAR-DNT cells (RJMty19) after infusion, and preliminary efficacy in systemic lupus
 erythematosus (SLE) subjects.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06340490
Non-Device Trial